Kumar, Roshan
Vitvitsky, Victor
Sethaudom, Apichaya
Singhal, Rashi
Solanki, Sumeet
Alibeckoff, Sydney
Hiraki, Harrison L. http://orcid.org/0000-0002-6199-0744
Bell, Hannah N.
Andren, Anthony
Baker, Brendon M.
Lyssiotis, Costas A.
Shah, Yatrik M. http://orcid.org/0000-0002-2487-4816
Banerjee, Ruma http://orcid.org/0000-0001-8332-3275
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM130183, R01CA248160, R01CA148828, R01CA245546)
Article History
Received: 13 March 2023
Accepted: 20 February 2024
First Online: 20 March 2024
Competing interests
: C.A.L. has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics and T-Knife Therapeutics and is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer and targeting the GOT1 pathway as a therapeutic approach (US Patent number 2015126580-A1, 5 July 2015; US Patent number 20190136238, 9 May 2019; International Patent number WO2013177426-A2, 23 April 2015). The remaining authors declare no competing interests.